HC Wainwright Reaffirms Buy Rating for Actinium Pharmaceuticals (NYSE:ATNM)

HC Wainwright restated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research note published on Tuesday,Benzinga reports. They currently have a $4.00 target price on the stock.

Actinium Pharmaceuticals Trading Up 1.1 %

Shares of Actinium Pharmaceuticals stock opened at $1.89 on Tuesday. The company has a 50-day moving average of $1.25 and a two-hundred day moving average of $1.45. Actinium Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $10.24. The stock has a market cap of $58.96 million, a PE ratio of -1.36 and a beta of 0.10.

Institutional Trading of Actinium Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP purchased a new position in shares of Actinium Pharmaceuticals in the third quarter valued at $112,000. Geode Capital Management LLC grew its stake in Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after acquiring an additional 19,843 shares during the last quarter. Barclays PLC increased its holdings in Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after acquiring an additional 32,784 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in Actinium Pharmaceuticals during the 4th quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC raised its position in Actinium Pharmaceuticals by 25.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after acquiring an additional 42,770 shares during the last quarter. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).